Multiple Myeloma Awareness Month: When the Doctor Becomes the Caregiver

Read More

Vitiligo after alemtuzumab treatment: Secondary autoimmunity is not all about B cells

Ruck et al.
Neurology
December 2018
Authors and Affiliates
Ruck T1, Pfeuffer S2, Schulte-Mecklenbeck A2, Gross CC2, Lindner M2, Metze D2, Ehrchen J2, Sondermann W2, Pul R2, Kleinschnitz C2, Wiendl H2, Meuth SG2, Klotz L2. 1 From the Clinic of Neurology with Institute of Translational Neurology (T.R., S.P., A.S.-M., C.C.G., M.L., H.W., S.G.M., L.K.) and Department of Dermatology (D.M., J.E.), University of Münster; and Departments of Dermatology, Venereology, and Allergology (W.S.) and Neurology (R.P., C.K.), University School of Medicine Essen-Duisburg, Essen, Germany. tobias.ruck@ukmuenster.de. 2 From the Clinic of Neurology with Institute of Translational Neurology (T.R., S.P., A.S.-M., C.C.G., M.L., H.W., S.G.M., L.K.) and Department of Dermatology (D.M., J.E.), University of Münster; and Departments of Dermatology, Venereology, and Allergology (W.S.) and Neurology (R.P., C.K.), University School of Medicine Essen-Duisburg, Essen, Germany.